False positive serum biochemical screening and subsequent fetal loss in women less than 35 years of age

Heyl, 1990, Maternal serum screening for aneuploid pregnancies by alpha-fetoprotein, hCG and unconjugated estriol, Obstet Gynecol, 76, 1025 MacDonald, 1991, Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age, Obstet Gynecol, 77, 63 Haddow, 1992, Prenatal screening for Down's syndrome with use of maternal serum markers, N Engl J Med, 327, 588, 10.1056/NEJM199208273270902 Philips, 1992, Maternal serum screening for fetal Down's syndrome in women less than 35 years of age using alpha-fetoprotein, hCG and unconjugated estriol: a prospective 2-year study, Obstet Gynecol, 80, 353 Spencer, 1993, Prospective study of prenatal screening for Down's syndrome with free-human chorionic gonadotrophin, BMJ, 307, 764, 10.1136/bmj.307.6907.764 Burton, 1988, Outcome of pregnancy in patients with unexplained elevated or low levels of maternal serum alpha-fetoprotein, Obstet Gynecol, 72, 709 Milunski, 1989, Predictive values, relative risks, and overall benefits of high and low maternal serun (α-fetoprotein screening in singleton pregnancies: New epidemiologic data, Am J Obstet Gynecol, 161, 291, 10.1016/0002-9378(89)90501-2 Katz, 1990, Unexplained elevations of maternal serum AFP, Obstet Gynecol Surv, 45, 719, 10.1097/00006254-199011000-00001 Waller, 1991, Second-trimester maternal serum alpha-fetoprotein levels and the risk of subsequent fetal death, N Engl J Med, 325, 6, 10.1056/NEJM199107043250102 Waller, 1996, The association between maternal serum alpha-fetoprotein and preterm birth, small for gestational age infants, pre-eclampsia, and placental complications, Obstet Gynecol, 88, 816, 10.1016/0029-7844(96)00310-9 Conen, 1992, The association between unexplained second-trimester maternal hCG elevation and pregnancy complications, Obstet Gynecol, 80, 83 Sorensen, 1993, Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension, Am J Obstet Gynecol, 169, 834, 10.1016/0002-9378(93)90013-9 Pergament, 1995, Adverse pregnancy outcome after a false positive screen for Downs syndrome using multiple markers, Obstet Gynecol, 86, 255, 10.1016/0029-7844(95)00108-4 Kowalczyk, 1998, Association of low unconjugated estriol in the second trimester and adverse pregnancy outcome, Obstet Gynecol, 91, 396, 10.1016/S0029-7844(97)00677-7 Moore, 1989, A prospective evaluation of fetal movement screening to reduce the incidence of antepartum fetal death, Am J Obstet Gynecol, 160, 1075, 10.1016/0002-9378(89)90164-6 Wald, 1988, Maternal serum screening for Down syndrome in early pregnancy, BMJ, 297, 883, 10.1136/bmj.297.6653.883 Antsaklis, 2000, Genetic amniocentesis in women 20-34 years old: associated risks, Prenat Diagn, 20, 247, 10.1002/(SICI)1097-0223(200003)20:3<247::AID-PD794>3.0.CO;2-O Jauniaux, 1996, Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high risk pregnancies, Prenat Diagn, 12, 1129, 10.1002/(SICI)1097-0223(199612)16:12<1129::AID-PD9>3.0.CO;2-I Muller, 1996, Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for pre-eclampsia, Am J Obstet Gynecol, 175, 37, 10.1016/S0002-9378(96)70247-8 Morssink, 1997, The association between hypertensive disorders of pregnancy and abnormal second-trimester maternal serum levels of hCG and alpha-fetoprotein, Obstet Gynecol, 89, 666, 10.1016/S0029-7844(97)00088-4 Walton, 1999, Second-trimester serum chorionic gonadotropin concentrations and complications and outcome of pregnancy, N Engl J Med, 341, 2033, 10.1056/NEJM199912303412701 Hsu, 1994, Elevated serum human chorionic gonadotropin as evidence of secretory response in severe preeclampsia, Am J Obstet Gynecol, 170, 1135, 10.1016/S0002-9378(94)70108-3 Liepman, 1993, An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome, Am J Obstet Gynecol, 168, 1852 Ashour, 1997, The value of elevated second-trimester-human choriogonadotropin in predicting development of pre-eclampsia, Am J Obstet Gynecol, 176, 438, 10.1016/S0002-9378(97)70512-X Bashore, 1977, Plasma estriol values in high risk pregnancies, Am J Obstet Gynecol, 128, 371, 10.1016/0002-9378(77)90555-5 Distler, 1978, Unconjugated estriol and total plasma estriol in the management of pregnant diabetic patients, Am J Obstet Gynecol, 130, 424, 10.1016/0002-9378(78)90284-3 Simpson, 1987, Maternal serum alpha-fetoprotein screening in 1987, Obstet Gynecol, 69, 134 Hsieh, 1997, Prediction of adverse perinatal outcome by maternal serum screening for Down syndrome in an asian population, Obstet Gynecol, 89, 937, 10.1016/S0029-7844(97)00151-8 Berkeley, 1983, Elevated maternal serum a-fetoprotein levels associated with breakdown in fetal-maternal-placental barrier, Am J Obstet Gynecol, 146, 859, 10.1016/0002-9378(83)91091-8 Katz, 1987, Maternal floor infarction of the placenta associated with elevated second trimester serum alpha-fetoprotein, Am J Perinatol, 4, 225, 10.1055/s-2007-999778 Boyd, 1992, Why might maternal serum alpha-fetoprotein be high in pregnancies in which the fetus is normally formed?, Br J Obstet Gynaecol, 99, 93, 10.1111/j.1471-0528.1992.tb14461.x Dungan, 1994, Positive serum screening for fetal Down syndrome does not predict adverse pregnancy outcome in absence of fetal aneuploidy, J Soc Gynecol Invest, 1, 55, 10.1177/107155769400100111 Chapman, 1997, Pregnancy outcomes following false-positive multiple marker screening tests, Am J Perinatol, 14, 475, 10.1055/s-2007-994183 Ogle, 2000, Serum screening for Downs syndrome and adverse pregnancy outcomes: a case–controlled study, Prenat Diagn, 20, 96, 10.1002/(SICI)1097-0223(200002)20:2<96::AID-PD766>3.0.CO;2-# Wolf, 2000, Triple marker screening and pregnancy outcomes: statistical methods and results, Obstet Gynecol, 95, 43, 10.1016/S0029-7844(00)00673-6